MUNJAL SHOWA LTD. Q1 FY27 Results

Munjal Showa's standalone revenue from operations rose 21.5% YoY to ₹347.50 Cr (₹286.04 Cr in Q1 FY26), while standalone PAT climbed 35.5% YoY to ₹11.23 Cr (₹8.28 Cr a year ago), with basic EPS at ₹2.81 versus ₹2.07. Sequentially, revenue was flat (+0.1% versus ₹347.07 Cr in Q4 FY26), but PAT swung from a reported loss of ₹0.05 Cr in Q4 FY26 to a ₹11.23 Cr profit — that prior-quarter loss was a balancing figure between audited full-year and nine-month numbers (note 5) that absorbed the full year's ₹2.20 Cr exceptional charge, so the QoQ 'turnaround' is largely a base-quarter accounting artefact rather than an operating inflection.

Margins expanded on both counts: net profit margin (PAT/total income) improved to 3.11% from 2.79% YoY, and the EBITDA-level operating margin widened to about 0.70% from 0.55%. The improvement sits mainly on cost of materials, which eased to 77.8% of revenue from 78.9% a year ago, even as employee costs rose to ₹33.82 Cr (9.7% of revenue) from ₹27.98 Cr (9.8%) and other expenses grew to ₹37.23 Cr from ₹33.12 Cr. Other income of ₹13.07 Cr (versus ₹11.01 Cr YoY) continues to do noticeable work in converting a near-breakeven core operating result into a mid-single-digit-crore-plus PBT, underscoring how thin the underlying auto-component margin still is for this business.

The stock went into the print at ₹145.75, up 11.3% over the past month of trading.

For context: this is the second-highest quarterly PAT of the last 6 quarters; PAT has now risen for 2 consecutive quarters.

No exceptional items in the current or year-ago quarter — the YoY growth is clean, unadjusted

No subsidiary, associate or JV as on June 30, 2026 — standalone is the only basis

There is no management guidance on record and no formal analyst/brokerage coverage or consensus estimate could be found for this print, so both vs-guidance and vs-street reads are unknown rather than a miss or beat. No management press release accompanied this filing beyond the standard board-outcome letter and notes. Corporate developments this quarter include MCA's approval of Hitoshi Fukagawa as Joint MD (July 15, 2026), a 225% final FY26 dividend with record date August 5, 2026, and the 41st AGM scheduled for August 24, 2026 — none of these directly explain the operating numbers but confirm continuity in the leadership and shareholder-return calendar around the print.